Chemours Company (The) (NYSE:CC) SVP David C. Shelton sold 13,397 shares of the firm’s stock in a transaction that occurred on Tuesday, October 10th. The shares were sold at an average price of $55.00, for a total transaction of $736,835.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

David C. Shelton also recently made the following trade(s):

  • On Thursday, August 31st, David C. Shelton sold 13,337 shares of Chemours Company (The) stock. The shares were sold at an average price of $48.48, for a total transaction of $646,577.76.

Shares of Chemours Company (NYSE CC) traded up 0.42% during trading on Thursday, hitting $55.35. 1,454,522 shares of the stock were exchanged. Chemours Company has a one year low of $14.66 and a one year high of $55.55. The stock’s 50 day moving average price is $52.06 and its 200 day moving average price is $52.06. The stock has a market cap of $10.23 billion, a PE ratio of 36.22 and a beta of 3.59.

Chemours Company (The) (NYSE:CC) last posted its quarterly earnings results on Wednesday, August 2nd. The specialty chemicals company reported $0.87 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.85 by $0.02. The business had revenue of $1.59 billion for the quarter, compared to analyst estimates of $1.49 billion. Chemours Company (The) had a return on equity of 122.97% and a net margin of 4.96%. The business’s revenue was up 14.8% compared to the same quarter last year. During the same period in the prior year, the company posted $0.27 EPS. Equities research analysts predict that Chemours Company will post $3.54 EPS for the current year.

The company also recently declared a quarterly dividend, which was paid on Friday, September 15th. Investors of record on Thursday, August 17th were given a dividend of $0.03 per share. This represents a $0.12 annualized dividend and a dividend yield of 0.22%. The ex-dividend date was Tuesday, August 15th. Chemours Company (The)’s dividend payout ratio is currently 8.11%.

WARNING: This piece was first published by American Banking News and is the property of of American Banking News. If you are reading this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2017/10/12/chemours-company-the-cc-svp-david-c-shelton-sells-13397-shares.html.

CC has been the topic of several recent analyst reports. Argus reiterated a “buy” rating and issued a $55.00 price target (up from $50.00) on shares of Chemours Company (The) in a research note on Thursday, August 10th. Jefferies Group LLC reiterated a “buy” rating and issued a $48.00 price target on shares of Chemours Company (The) in a research note on Friday, June 16th. Citigroup Inc. upgraded shares of Chemours Company (The) from a “neutral” rating to a “buy” rating and increased their price target for the company from $43.00 to $45.00 in a research note on Wednesday, July 5th. BidaskClub upgraded shares of Chemours Company (The) from a “hold” rating to a “buy” rating in a research note on Wednesday, July 12th. Finally, Zacks Investment Research lowered shares of Chemours Company (The) from a “buy” rating to a “hold” rating in a research note on Wednesday, July 12th. One equities research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $52.75.

Several hedge funds have recently bought and sold shares of CC. Victory Capital Management Inc. grew its stake in Chemours Company (The) by 292.0% during the 2nd quarter. Victory Capital Management Inc. now owns 657,810 shares of the specialty chemicals company’s stock worth $24,944,000 after buying an additional 489,990 shares during the last quarter. Los Angeles Capital Management & Equity Research Inc. grew its stake in Chemours Company (The) by 264.7% during the 2nd quarter. Los Angeles Capital Management & Equity Research Inc. now owns 42,669 shares of the specialty chemicals company’s stock worth $1,618,000 after buying an additional 30,970 shares during the last quarter. Virginia Retirement Systems ET AL bought a new position in Chemours Company (The) during the 2nd quarter worth $1,460,000. Alps Advisors Inc. bought a new position in Chemours Company (The) during the 2nd quarter worth $202,000. Finally, ING Groep NV bought a new position in Chemours Company (The) during the 2nd quarter worth $6,630,000. 72.90% of the stock is currently owned by institutional investors and hedge funds.

About Chemours Company (The)

The Chemours Company is a provider of performance chemicals. The Company operates through three segments: Titanium Technologies, Fluoroproducts and Chemical Solutions. The Titanium Technologies segment is a producer of titanium dioxide (TiO2). The Fluoroproducts segment is a provider of fluoroproducts, including refrigerants and industrial fluoropolymer resins.

Insider Buying and Selling by Quarter for Chemours Company (The) (NYSE:CC)

Receive News & Ratings for Chemours Company (The) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours Company (The) and related companies with MarketBeat.com's FREE daily email newsletter.